Indietro

Short Communication

Factors affecting treatment success: from pharmacology to drug resistance

SC 25
The impact of pharmacogenetics on long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting
Abstract
SC 26
The case of dolutegravir plus darunavir antiretroviral regimens: Is it always useful to double the drug doses?
Abstract
SC 27
Comparative analysis of islatravir and tenofovir in vitro activity in NRTI resistant HIV-1 harboring the M184V/I mutation
Abstract
SC 28
Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy according to subtype over the period 2017-2023
Abstract
SC 29
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed people with HIV-1 switching to modern antiretroviral regimens
Abstract
SC 30
Ultra-deep sequencing of near full-length HIV-1 genomes for detecting natural resistance to lenacapavir and fostemsavir
Abstract
| Privacy policy | Cookies policy | Termini e condizioni di utilizzo |
© Effetti srl
P. IVA 10756900154
×

Commento audio

Chiudi